Ono Venture Investment

Harness Therapeutics is a private biotechnology company focused on developing SINEUPs, a novel class of therapeutic RNAs that upregulate protein expression with precise control and specificity. The company’s platform uses mRNA-targeted oligonucleotides to modulate post-transcriptional protein synthesis, enabling disease-modifying protein upregulation for conditions that have resisted traditional approaches. Its work centers on central nervous system and ophthalmologic disorders, with potential applications across multiple therapy areas by expanding the druggable proteome beyond what conventional small molecules, biologics, or gene therapies can address.

AIRNA is a biotechnology company specializing in the development of RNA editing therapies. Its platform enables the creation of therapeutics designed to treat both rare and common diseases, with the goal of improving patients' health.

Mozart Therapeutics is a biotechnology company specializing in the development of disease-modifying therapies for autoimmune and inflammatory diseases. It focuses on creating first-in-class CD8 Treg modulators to restore long-term immune balance and prevent progressive damage caused by autoreactive immune responses.

Violet Therapeutics is a pre-clinical stage biotechnology company focused on drug discovery for central nervous system diseases. The company utilizes innovative platforms that identify, map, and analyze cellular connectomes through barcoded viral tracing, offering insights into cell-cell interactions at a single-cell level. This approach aims to facilitate advancements in the understanding and treatment of neuroinflammation. Co-founded by Mass General Brigham Ventures and researchers from Brigham & Women’s Hospital, Violet Therapeutics is committed to exploring novel therapeutic targets to develop effective treatments for complex neurological conditions.

Curreio is a biotechnology company that develops a platform for drug discovery using structural analysis with cryo-electron microscopy. The platform enables observation of in vivo structures by freezing samples without staining, supporting the discovery and analysis of life-saving drugs through structural analysis–based approaches.

Mediar Therapeutics is a pre-clinical stage biotechnology company focused on developing therapeutics to treat fibrosis in chronically damaged organs. It designs antibodies that neutralize mediators driving fibrotic activity with the aim of halting and reversing fibrosis to improve patient outcomes. Founded in 2019 and based in Cambridge, Massachusetts, the company targets key fibrotic mediator proteins to address late-stage disease with precision and efficacy.

Switch Therapeutics is a biotechnology company founded in 2020 and based in San Francisco, California. The company focuses on revolutionizing RNA interference (RNAi) therapies by developing biomarker-gated genetic medicines. These innovative therapies utilize nucleic acid nanotechnology and RNAi science to target a variety of diseases, particularly those affecting the central nervous system and other systemic conditions with significant unmet medical needs. Switch Therapeutics aims to provide healthcare providers with RNA molecules and therapies that can be activated selectively in specific cells, enhancing the precision of treatments for central nervous system diseases.

Casma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing innovative therapeutic strategies centered on the natural cellular process of autophagy. Founded in 2017, the company aims to enhance autophagy to improve the clearance of unwanted proteins, organelles, and pathogens, thereby addressing significant medical challenges. Casma Therapeutics is advancing preclinical programs targeting various conditions, including muscle disorders, liver disease, inflammatory disorders, and neurodegenerative diseases. By harnessing and manipulating the autophagy system, the company seeks to arrest or reverse disease progression, ultimately enabling physicians to meet unmet medical needs and provide effective treatments for patients with serious health issues.

Photys Therapeutics is a biopharmaceutical company focused on developing bifunctional small molecules that provide precise control over protein post-translational modifications. This innovative platform allows for the restoration of protein function, repair of cellular signaling pathways, and enhancement of the body's natural disease-fighting abilities. Co-founded by prominent chemist Amit Choudhary from the Broad Institute and the Longwood Fund, Photys is supported by a scientific advisory board that includes renowned experts from institutions such as MIT, Salk Institute, and Berkeley. The company's unique approach aims to advance therapeutic options in the healthcare industry, particularly by targeting kinases and potentially phosphatases, to address various diseases effectively.

Immunitas Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing targeted therapeutics for patients with complex cancers. Founded in 2019, the company utilizes a single-cell sequencing platform to analyze the biology of immune cells within human tumors. This innovative approach allows Immunitas to identify novel drug targets and develop key biomarkers that guide patient selection for their therapies. By emphasizing research rooted in human biology, Immunitas aims to bridge the gap between laboratory discoveries and clinical applications. The company is advancing multiple programs toward early human studies, leveraging its expertise in antibody discovery and engineering to create effective treatments that modulate identified targets.

Curreio is a biotechnology company that develops a platform for drug discovery using structural analysis with cryo-electron microscopy. The platform enables observation of in vivo structures by freezing samples without staining, supporting the discovery and analysis of life-saving drugs through structural analysis–based approaches.

Mediar Therapeutics is a pre-clinical stage biotechnology company focused on developing therapeutics to treat fibrosis in chronically damaged organs. It designs antibodies that neutralize mediators driving fibrotic activity with the aim of halting and reversing fibrosis to improve patient outcomes. Founded in 2019 and based in Cambridge, Massachusetts, the company targets key fibrotic mediator proteins to address late-stage disease with precision and efficacy.